Diabetes Clinical Trial
Official title:
The Safety and Efficacy of QS-M Needle -Free Injector Versus Needle-insulin Pen as a Drug Carrier for Controlling the Blood Glucose in T2DM:a Randomized, Parallel Controlled, Open-label, Multicenter Trial
NCT number | NCT03243903 |
Other study ID # | KSE01 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | August 18, 2017 |
Est. completion date | November 8, 2018 |
Verified date | March 2020 |
Source | Beijing QS Medical Technology Co., Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
In this study, QS-M needle-free injector and needle-insulin pen were used as a drug carrier to control blood glucose in type 2 diabetic patients(T2DM).The efficacy and safety of QS-M needle-free injector and needle-insulin pen were evaluated and compared.This is a needle-insulin pen as control group, using a prospective, multicenter, randomized, open, parallel grouping study.
Status | Completed |
Enrollment | 427 |
Est. completion date | November 8, 2018 |
Est. primary completion date | November 8, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: 1. have been diagnosed with type 2 diabetes; (A) have been treated with insulin (premixed or basal) subcutaneous injection therapy (without limitation or combined oral hypoglycemic agents); (B) the subjects with poor blood sugar control is taking oral hypoglycemic agents or living interventions need Initiating insulin therapy (see Appendix 1 for initiating treatment regimens); 2. adults aged 18-75 years, women of childbearing age need to take adequate contraceptive measures to reduce the pregnancy risk to the minimum; 3. injection of insulin and / or oral hypoglycemic agents = 3 months before enroll the study, the insulin dose adjustment = 10% within 1 month before enrolling (adjustment = (the maximum dose within a month - the minimum dose) / Final dose (dose of the day before the visit) × 100%); 4. have a HbAlc value (detected by NGSP approved method) between 7.5-11% ; 5. BMI = 32kg / m2, the body weight remained relatively stable, body weight change of no more than 10% at least 3 months before screening, 6. Male subjects hemoglobin=12g/dl (= 120g / L), female subjects hemoglobin = 11g / dl (= 110g / L); 7. serum creatinine <1.5 mg / dL for male subjects, serum creatinine <1.4 mg / dL for female subjects; 8. have not participated in other clinical studies related diabetes treatment within 3 months ; 9. be volunteered to participate in this clinical study and signed informed consent. Exclusion Criteria: 1. the persons who attend or perform this study; 2. women in pregnancy or lactation; 3. have frequent severe hypoglycaemia in one month; have blood glucose control adverse events like diabetic ketoacidosis or hyperosmotic diabetic coma within half a year; 4. have severe cardiovascular events in the past 6 months, such as myocardial infarction, acute coronary syndrome, cerebral infarction, cardiovascular and cerebrovascular surgery; 5. have used hormones or immunosuppressive agents, or have immunologic deficiency disease; 6. have end-stage renal disease, and are receiving dialysis treatment; 7. have of history of cancer within 5 years; 8. have history of severe mental instability; 9. have long-term alcohol abuse or drug abuse history; 10. have Skin lesions in the insulin injection site; 11. have history of anemia caused by hemoglobinopathy (such as sickle cell red blood cell anemia, thalassemia, sideroblastic anemia) or any other course; 12. have critically ill, or life expectancy is less than one year; 13. difficult to evaluate the effectiveness and safety of the device intervention; 14. have a clear infection history within a month, such as pneumonia; 15. have active liver disease (AST> 3 times of normal upper limit or ALT> 3 times of normal upper limit); 16. have history of acute pancreatitis within a month; 17. have history of insulin allergy; 18. have been expected to have poor compliance and can not be treated according to the research protocol; 19. other cases that investigators believe that the subject may fail to complete the study or may have a significant impact. |
Country | Name | City | State |
---|---|---|---|
China | Peking University People 's Hospital | Beijing | Beijing |
Lead Sponsor | Collaborator |
---|---|
Beijing QS Medical Technology Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | The rate of glycosylated hemoglobin | The rate of glycosylated hemoglobin (according to the percentage of HbA1c <7.0% of the total number of subjetcs at 16th weeks). | 16 weeks | |
Other | SF-36 | Quality of Life Questionnaire (SF-36) (the changes comparison about SF-36 quality of life score between 16th weeks of subjects and baseline. | 16 weeks | |
Other | Insulin dose | Insulin dose (the actual total dose of injected insulin of the first day and the day before the 1st,2nd,4th,6th,8th,12th,16th weeks' interview). | 16 weeks | |
Other | Insulin treatment compliance | Insulin treatment compliance (recording whether the subjects obey the program to inject insulin at the specified time point in the 1st, 2nd, 4th, 6th, 8th, 12th, 16th weeks). | 16 weeks | |
Other | Subject Satisfaction | Subject Satisfaction ( the 16th Week overall satisfaction for the use of injectable equipment). At the end of the trial (16th week),recording and comparing the experimental group / control subjects the overall satisfaction of the injector used in the trial. According to the subjective satisfaction to scoring, the satisfaction score form 0 to 10. With the minimum score 0 for the least satisfied and the maximum score 10 for the most satisfied. | 16weeks | |
Primary | glycosylated hemoglobin (HbA1c) | The changes in glycosylated hemoglobin (HbA1c) value between the 16th week of treatment and the start of the adjustment period (using NGSP approved detection method to detect the glycosylated hemoglobin values) . | 16weeks | |
Secondary | Self-monitoring of blood glucose(SMBG) | SMBG blood glucose value (on the first day and two days before the 1st, 2nd, 4th, 6th, 8th, 12th, 16th weeks interview, test the values before and 2 hours after the three meals and before sleeping). | 16 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05594446 -
Morphometric Study of the Legs and Feet of Diabetic Patients in Order to Collect Data Intended to be Used to Measure by Dynamometry the Pressures Exerted by Several Medical Compression Socks at the Level of the Forefoot
|
||
Completed |
NCT03975309 -
DHS MIND Metabolomics
|
||
Completed |
NCT01855399 -
Technologically Enhanced Coaching: A Program to Improve Diabetes Outcomes
|
N/A | |
Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
Recruiting |
NCT04984226 -
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
|
Phase 2 | |
Recruiting |
NCT05007990 -
Caregiving Networks Across Disease Context and the Life Course
|
||
Active, not recruiting |
NCT04420936 -
Pragmatic Research in Healthcare Settings to Improve Diabetes and Obesity Prevention and Care for Our Program
|
N/A | |
Recruiting |
NCT03549559 -
Imaging Histone Deacetylase in the Heart
|
N/A | |
Completed |
NCT04903496 -
Clinical Characteristics and Disease Burden of Diabetic Patients Based on Tianjin Regional Database
|
||
Completed |
NCT01437592 -
Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT03390179 -
Hyperglycemic Response and Steroid Administration After Surgery (DexGlySurgery)
|
||
Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
Recruiting |
NCT05294822 -
Autologous Regenerative Islet Transplantation for Insulin-dependent Diabetes
|
N/A | |
Completed |
NCT04427982 -
Dance and Diabetes/Prediabetes Self-Management
|
N/A | |
Completed |
NCT02356848 -
STEP UP to Avert Amputation in Diabetes
|
N/A | |
Completed |
NCT03292185 -
A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects
|
Phase 1 | |
Active, not recruiting |
NCT05477368 -
Examining the Feasibility of Prolonged Ketone Supplement Drink Consumption in Adults With Type 2 Diabetes
|
N/A | |
Completed |
NCT04496401 -
PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus
|
Phase 4 |